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ReviewNon-HLA Genetic Factors and Their Influence on
Heart Transplant Outcomes: A Systematic Review
Jessica van Setten, PhD,1 Evangeline G. Warmerdam, MD,1 Olivier Q. Groot, BSc,1 Nicolaas de Jonge, MD,1
Brendan Keating, PhD,2 and Folkert W. Asselbergs, MD, PhD1,3,4,5Background. Improvement of immunosuppressive therapies and surgical techniques has increased the survival rate after heart
transplantation. Nevertheless, a large number of patients still experience complications, such as allograft rejection, vasculopathy,
kidney dysfunction, and diabetes in response to immunosuppressive therapy. Variants in HLA genes have been extensively studied
for their role in clinical outcomes after transplantation, whereas the knowledge about non-HLA genetic variants in this setting is still
limited. Non-HLA polymorphisms are involved in the metabolism of major immunosuppressive therapeutics and may play a role in
clinical outcomes after cardiac transplantation. This systematic review summarizes the existing knowledge of associations between
non-HLA genetic variation and heart transplant outcomes.Methods.The current evidence available on genetic polymorphisms as-
sociated with outcomes after heart transplantation was identified by a systematic search in PubMed and Embase. Studies reporting
on polymorphisms significantly associated with clinical outcomes after cardiac transplantation were included.Results.A total of 56
studies were included, all were candidate gene studies. These studies identified 58 polymorphisms in 36 genes that were associated
with outcomes after cardiac transplantation. Variants in TGFB1, CYP3A5, and ABCB1 are consistently replicated across multiple
studies for various transplant outcomes. Conclusions. The research currently available supports the hypothesis that non-HLA
polymorphisms are associated with clinical outcomes after heart transplantation. However, many genetic variants were only identified
in a single study, questioning their true effect on the clinical outcomes tested. Further research in larger cohorts with well-defined phe-
notypes is warranted.
(Transplantation Direct 2019;5: e422; doi: 10.1097/TXD.0000000000000859. Published online 21 January, 2019.)Heart transplantation is still considered to be the therapyof choice for patients with end-stage heart failure re-
fractory to optimal medical and surgical therapy.1 Every
year, over 4000 heart transplantations are performed world-
wide, the majority being in the United States and Europe.2
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Transplantation DIRECT ■ 2019greatly in the last decades, mainly due to evolving immuno-
suppressant therapies and improvement in surgical tech-
niques. The current 1-year survival is being reported at
greater than 85%.3 However, ~15% of recipients suffers at
least 1 episode of acute cellular rejection in the first year after
transplantation.3 High doses of immunosuppressive drugs
are not only needed to prevent rejection, but are also associ-
ated with an increased risk of infections, malignancies, and
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have been studied extensively for their role in the occurrence
of acute and chronic rejection in solid organ transplanta-
tion.5 In contrast, the effect of minor histocompatibility
antigens (mHA) on transplant outcomes is largely un-
known. These mHA polymorphisms could potentially lead
to genetic differences between donors and recipients, acti-
vating the immune system of the recipient and conse-
quently cause acute allograft rejection. This is supported
by allograft rejection being observed in kidney transplants
and stem cell transplantations between HLA identical sib-
lings.6 Recent findings suggest that mHA polymorphisms
are not only involved in the development of acute rejec-
tion, but also determine the renal function posttransplan-
tation and play a role in the development of chronic
rejection.7-9 Another group of non-HLA polymorphisms that
maybe involved in transplant outcomes are those genetic variants
involved in drug metabolism. Pharmacogenomics studies have
identified dozens of polymorphisms influencing plasma levels of
a wide variety of drugs and other substances, some of which
may influence metabolism of drugs commonly prescribed to
transplanted patients.FIGURE 1. Literature search and study selection flowchart. SNP, singleThis systematic review provides an overview of the pub-
lished research on non-HLA genetics in heart transplanta-
tion. We included all studies that identified 1 or more
significant associations between genetic variants and any
heart transplant outcome, regardless of study design.
MATERIALS AND METHODS
An overview of the literature search and study selection is
shown in Figure 1.
Search
MEDLINE (PubMed) and Embase databases were searched
for all relevant literature published on non-HLA polymor-
phisms associated with clinical outcome after heart trans-
plantation. The search strategy included the terms “heart,”
“transplantation,” “gene,” and their synonyms and related
terms. Searches were restricted to human studies:
MEDLINE: human[MeSH Terms] AND (heart[Title/
Abstract] OR cardiac[Title/Abstract]) AND (transplant
[Title/Abstract] OR transplantation[Title/Abstract]) AND
(gene[Title/Abstract] OR SNP[Title/Abstract] OR poly-
morphism[Title/Abstract])nucleotide polymorphism.
© 2019 Wolters Kluwer van Setten et al 3Embase: human AND (heart:ab,ti OR cardiac:ab,ti) AND
(transplant:ab,ti OR transplantation:ab,ti) AND (gene:ab,ti
OR SNP:ab,ti OR polymorphism:ab,ti). Reference lists of in-
cluded articles, and previous reviewsweremanually searched
for additional relevant studies. Databases were searched
from their inception to July 10, 2018.
Inclusion Criteria
We included original research article published in peer-
reviewed scientific journals, reporting on the association of
genetic polymorphisms with clinical outcomes after heart
transplantation in pediatric and adult patients. Only articles
written in English were included.
Study Selection
Two reviewers independently screened titles and abstracts
to identify potentially relevant articles. Two reviewers ob-
tained and independently screened full text versions of poten-
tially eligible studies to determine their suitability for inclusion.
Studies were included on the basis of consensus agreement.
Data Extraction
Two investigators independently retrieved data from each
included study. The data collected for each study included
study name; first author; publication year; number of recipients,
donors and controls in the study; the number of pediatric pa-
tients included; mean duration of follow-up; polymorphism/
single nucleotide polymorphism (SNP) investigated; gene; refer-
ence SNP cluster ID (rsID) or primers for SNP; location of SNP;
investigated phenotype(s); use of immunosuppressive drugs; sta-
tistical test; and P value. In those studies that reported primers
instead of rsIDs, we queried the University of California, Santa
Cruz Genome Browser and Basic Local Alignment Search Tool
of the National Center for Biotechnology Information to try
identifying the rsIDs.
Data Analysis
The studies were searched for polymorphisms that were
significantly associated (P < .05) with 1 or more clinical
outcomes after heart transplantation. Associations wereTABLE 1.
Single nucleotide polymorphisms (SNPs) in ABCB1,CYP3A5, and
after cardiac transplantation
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ABCB1, ATP binding cassette subfamily B member 1; CYP3A5, cytochrome P450 family 3, subfamily A,categorized based on their phenotype: immunosuppressive
therapy, rejection and survival, cardiac function, kidney
function, lipids, and other phenotypes (Tables S1–S6,
SDC, http://links.lww.com/TXD/A172). Studies were ex-
cluded if they did not report a significant association related
to heart transplantation outcomes, or if analyses were con-
ducted in a mixed set of solid organ transplants with only a
small percentage of cardiac transplants. We assessed quality
of the individual studies by the following criteria: (1) selection
bias, (2) phenotype definition, (3) population structure
taken into account, (4) accuracy of genotypingmeasurement,
(5) Hardy-Weinberg equilibrium assessed, (6) multiple testing
correction, and (7) results consistent with other studies.RESULTS
The literature search included 2755 published results until
July 10, 2018, after removal of duplicates. A total of 86 articles
were screened full text. After screening, 56 articles with statisti-
cally significant associations between SNPs and clinical out-
comes after heart transplantation were eligible. Together, these
56 studies contained 107 significant SNP-phenotype associa-
tions, and included a total of 7030 recipients, 3059 donors,
and 1308 controls. Some studies cohorts published multiple
studies using the same samples, so the number of unique sam-
ples is lower. Forty-five studies included adult patients only, 9
studies included only pediatric patients and 2 studies included
patients of all ages. All included studies were candidate gene
studies. A total of 58 polymorphisms in 36 geneswere identified
to be associated with clinical outcomes after heart transplanta-
tion. Results per phenotype group can be found in Tables S1–
S6, SDC (http://links.lww.com/TXD/A172).None of the studies
fulfilled all of our quality criteria. Especially selection bias, pop-
ulation structure, Hardy-Weinberg equilibrium, accuracy of
genotyping measurement, and multiple testing correction were
hardly ever taken into account. Phenotype definition quality
varies across clinical outcomes. For example, immunosuppres-
sive drug level measures were explained in detail in all studies,
whereas rejection type or grade was not specified in approxi-
mately 25% of studies. Therefore, we decided to only useTGFB1 are associated to a diverse range of clinical outcomes
Phenotype References
Cyclosporin levels 10






Tacrolimus levels, dose, clearance 13,16-19
Renal function 20
Acute rejection 21
Cardiac allograft vasculopathy 22-26
All rejection (chronic and acute) 24
End-stage renal failure, renal function 27-29
member 5; TGFB1, transforming growth factor beta-1.
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ABCB1, CYP3A5, and TGFB1, associated with heart trans-
plant outcomes (Table 1).DISCUSSION
This literature review gives a comprehensive overview of
all non-HLApolymorphisms that have been implicated to affect
outcomes after heart transplantation. A total of 56 studies were
included, all were candidate gene studies. Fifty-eight polymor-
phisms in 36 different genes were identified. Even though the
field of genetics in heart transplantation remains largely unex-
plored, the identification of multiple polymorphisms supports
the theory that non-HLA polymorphisms are involved in clini-
cal outcomes after heart transplantation.
Although many variants and genes were only significantly
associated to heart transplant outcomes in a single study,
some were identified in multiple studies. Especially SNPs in
ABCB1,CYP3A5, andTGFB1, summarized in Table 1, were
consistently replicated for a subset of traits.
ATP Binding Cassette Subfamily B Member 1
The ATP binding cassette subfamily B member 1 (ABCB1)
gene on chromosome 7 encodes for a transporter protein, P-
glycoprotein, which is expressed in the liver, pancreas, kidney,
and intestines. This protein is involved in multidrug resistance
and is often linked to the development of resistance to anticancer
drugs.30,31 TogetherwithCYP3A, it is involved in the transporta-
tion and biotransformation of cyclosporine and tacrolimus. It is
suspected to be associated with inflammatory bowel disease32
and colchicine resistance.33 Several polymorphisms, rs1045642
within exon 26, rs1128503 within exon 12, rs2032582 within
exon 21, rs2235013, and rs2235033, both within an intron,
were associatedwith cyclosporine levels in heart transplant recip-
ients.10 Two reviews on severalCYP3A andABCB1 SNPs show
conflicting results on the influence of rs1045642, rs2032582, and
rs1128503 on both cyclosporine and tacrolimus pharmacoki-
netics and drug response solid organ transplant recipients.34-36
It is hypothesized that these SNPs could induce a lower
P-glycoprotein activity, which could lead to less cyclosporine
to be removed from the cells, thus increasing the bioavailabil-
ity.37 Two studies found associations between ABCB1 SNPs
and acute rejection after heart transplantation, which may be
attributed to altered cellular levels of immunosuppressants.14,15
Cytochrome P450 Family 3, Subfamily A, Member 5
The cytochrome P450 family 3, subfamily A, member 5
(CYP3A5) gene on chromosome 7 encodes an enzyme of
the cytochrome P450 family, mostly expressed in the liver,
which is involved in the metabolism of a large variety of
drugs and the synthesis of cholesterol and other lipids.38
CYP3A5 is known to be involved in the development of es-
sential hypertension in humans39 and to influence the re-
quired dose of the calcineurin inhibitors cyclosporin and
tacrolimus in solid organ transplantation recipients. The
rs776746 G allele is a loss-of-function allele, which disrupts
a splice site. This leads to expression of a nonfunctional en-
zyme, resulting in reduced metabolization of tacrolimus and
thus higher concentrations.40,41 Multiple studies demon-
strate an association between the SNP rs776746 and the ta-
crolimus level or dose for heart transplant recipients.13,16-18
Renal dysfunction after cardiac transplantation is an adverse
outcome frequently observed, mainly due to the prescriptionof calcineurin inhibitors; they are known to be nephrotoxic
and involved in the development of hypertension, which can
also result in renal dysfunction.42 Two genomewide association
studies (GWAS) in African American and European kidney
transplant recipients, respectively, identified several CYP3A5
SNPs to be associated with tacrolimus through concentra-
tions, including rs776746.43,44 One study found this SNP to
be associated with renal function postheart transplantation.20
Transforming Growth Factor Beta-1
The transforming growth factor beta-1 (TGFB1) gene on
chromosome 19 encodes a cytokine that has a wide range
of functions and is involved in many biological processes,
such as embryogenesis, carcinogenesis and immune response.45
TGF-ß1 plays an especially large role in the regulation of T-
lymphocytes46 and is known to be of importance in a large
variety of disorders in humans, including coronary artery dis-
ease (CAD) and rejection after kidney transplantation.47-49
Two different polymorphisms in the TGFB1 gene were iden-
tified in relation to outcomes after heart transplantation:
rs1800470 in codon 10 and rs1800471 in codon 25. Several
studies found an association between rs1800471 and acute
cellular rejection, and/or CAD posttransplantation.21-24,49
However, these findings were inconsistent because 3 studies
showed no significant association between acute cellular re-
jection and rs1800471,50-52 and another 3 studies failed to
find an association between this SNP and chronic rejec-
tion.25,52,53 Two studies found rs1800471 to be associated
with renal function after transplantation27,28 and 3 found
no significant association.54-56 The SNP rs1800470 was also
associated with accelerated CAD after transplantation25 and
with renal function posttransplantation.29
Many loci were published in only a single study, or tested
in multiple studies but could not be consistently replicated.
For instance, the IL10 SNP rs1800896 has been reported as
significantly associated with rejection in 3 studies (Table S2,
SDC, http://links.lww.com/TXD/A172).50,57,58 However, 6
other studies were not able to find a significant effect for
the same SNP on any form of rejection.52,53,59-62 Publication
bias, that is, the fact that negative findings are less likely to be
published, makes it even more difficult to establish the true
association between this SNP and rejection.
This lack of replication of findings could have various rea-
sons. First, sample sizes of most studies are limited, which re-
duces statistical power to detect significant associations.
Most transplant centers perform less than a few dozen of
heart transplants per year, making it difficult to collect larger
numbers of samples that are needed for genetic studies. Second,
the definitions of the investigated phenotype varied greatly. For
instance, the definition of acute rejection varied from “any
histological evidence of rejection” to “acute cellular rejection
grade 2R or higher.” If the biological mechanisms leading to
clinical outcomes are different, the underlying genes and loci
involved may also vary. Combining clinical outcomes may
lead to more noise and thus less statistical power, whereas
testing a gene found for 1 outcome for association with a
slightly different outcome,may lead to nonreplication. Third,
patient characteristics of the included studies were heteroge-
neous, which is not unexpected because of the limited num-
bers of transplants performed each year. The studies
samples differ for instance in ethnicity, sex, age, and underly-
ing disease causing the need for heart transplantation.
© 2019 Wolters Kluwer van Setten et al 5Fourth, the vast majority of studies did not correct for potential
confounding due to population structure or cryptic relatedness.
Also,many studies did not correct forHLA type in the recipient,
or HLA mismatches between donors and recipients. Lastly,
many reports studied more than 1 polymorphisms and did
not correct for multiple testing, most likely resulting in a
number of false-positive results. Overall, the quality of the
candidate gene studies was limited, with none of the studies
fulfilling our quality criteria.
Candidate gene studies are hypothesis driven, assuming
that prior knowledge of the gene function will lead to identi-
fication of genetic variants associated with clinical traits.
Complex conditions, such as acute and chronic rejection or
renal dysfunction posttransplantation, are believed to be in-
fluenced bymultiple genetic polymorphisms that individually
contribute only a small proportion to the overall risk. Various
biological pathways are involved in the development of these
conditions, but in many cases, it is unclear which pathways
are involved or how important a specific pathway is. Thus,
a candidate gene study may not be ideal to identify SNPs re-
lated to clinical outcomes after heart transplantation.
Genomewide association studies, incorporating millions
of genetic variants, would likely be a more appropriate study
design because it has an agnostic approach. However, the
combination of a need for large sample sizes to be appropriately
powered to detect significance in a GWAS and the limited
amount of cardiac transplantations being performed could
prove to be challenging. This is reflected by the lack of
genomewide studies on heart transplant outcomes, and the
small number of GWAS on solid organ transplant outcomes
in general. Thus far, only 8 GWAS have been published in this
field, and all involved renal transplants.43,44,63-68 Outcomes in-
vestigatedweremedium-termgraft function, newonset diabetes
after transplantation, acute cellular rejection, and tacrolimus
concentrations.
More research into the genetic factors associated with out-
comes posttransplantation can lead to the discovery of novel
pathways or biological processes involved and a better un-
derstanding of already known biological pathways. Large
consortiums are key to allow these large-scale genetic analy-
ses, potentially testing tens of millions of genetic variants.
The International Genetics & Translational Research in
Transplantation Network (www.igenetrain.org) was de-
signed to this end, and now consist of more than 30 studies
with extensive phenotypic and genomics and other -omics
data.69,70 The ultimate goal is to use the knowledge from this
research to improve outcomes for transplant recipients, for
example, by better individualized dosing and selection of im-
munosuppressive medication and possibly even risk stratifi-
cation for adverse outcomes after heart transplantation.
Findings of this systematic review of current literature support
the hypothesis that non-HLA polymorphisms are involved in
outcomes after heart transplantation, but evidence for individual
SNPs associated with specific phenotypes is limited. Larger stud-
ies incorporating genetic variationona genomewide scalemaybe
able to discover novel loci and to validate known genetic varia-
tion associated to outcomes after cardiac transplantation.
REFERENCES
1. Mehra MR, Canter CE, Hannan MM, et al. The 2016 International Society
for Heart Lung Transplantation listing criteria for heart transplantation: a
10-year update. J Heart Lung Transplant. 2016;35:1–23.2. Lund LH, Edwards LB, Kucheryavaya AY, et al. The registry of the Interna-
tional Society for Heart and Lung Transplantation: thirty-first official adult
heart transplant report–2014; focus theme: retransplantation. J Heart
Lung Transplant. 2014;33:996–1008.
3. Lund LH, Khush KK, Cherikh WS, et al. The registry of the International
Society for Heart and Lung Transplantation: thirty-fourth adult heart trans-
plantation report—2017; focus theme: allograft ischemic time. J Heart
Lung Transplant. 2017;36:1037–1046.
4. Lopez MM, Valenzuela JE, Alvarez FC, et al. Long-term problems related
to immunosuppression. Transpl Immunol. 2006;17:31–35.
5. Jarcho J, Naftel DC, Shroyer TW, et al. Influence of HLA mismatch on re-
jection after heart transplantation: a multiinstitutional study. The Cardiac
Transplant Research Database Group. J Heart Lung Transplant. 1994;
13:583–595; discussion 595–586.
6. Ingulli E. Mechanism of cellular rejection in transplantation. Pediatr
Nephrol. 2010;25:61–74.
7. Holweg CT, Weimar W, Uitterlinden AG, et al. Clinical impact of cytokine
gene polymorphisms in heart and lung transplantation. J Heart Lung
Transplant. 2004;23:1017–1026.
8. Dragun D. Humoral responses directed against non-human leukocyte anti-
gens in solid-organ transplantation. Transplantation. 2008;86:1019–1025.
9. Almoguera B, Shaked A, Keating BJ. Transplantation genetics: current
status and prospects. Am J Transplant. 2014;14:764–778.
10. Jordan de Luna C, Herrero Cervera MJ, Sanchez Lazaro I, et al. Pharma-
cogenetic study of ABCB1 and CYP3A5 genes during the first year follow-
ing heart transplantation regarding tacrolimus or cyclosporine levels.
Transplant Proc. 2011;43:2241–2243.
11. Zheng HX, Webber SA, Zeevi A, et al. The impact of pharmacogenomic
factors on steroid dependency in pediatric heart transplant patients using
logistic regression analysis. Pediatr Transplant. 2004;8:551–557.
12. ZhengH,Webber S, Zeevi A, et al. TheMDR1polymorphisms at exons 21
and 26 predict steroid weaning in pediatric heart transplant patients.Hum
Immunol. 2002;63:765–770.
13. Zheng H, Webber S, Zeevi A, et al. Tacrolimus dosing in pediatric heart
transplant patients is related toCYP3A5 andMDR1 gene polymorphisms.
Am J Transplant. 2003;3:477–483.
14. Barnard JB, Richardson S, Sheldon S, et al. The MDR1/ABCB1 gene, a
high-impact risk factor for cardiac transplant rejection. Transplantation.
2006;82:1677–1682.
15. Sanchez-Lazaro I, Herrero MJ, Jordan-De Luna C, et al. Association of
SNPs with the efficacy and safety of immunosuppressant therapy after
heart transplantation. Pharmacogenomics. 2015;16:971–979.
16. Deininger KM, Vu A, Page RL 2nd, et al. CYP3A pharmacogenetics and
tacrolimus disposition in adult heart transplant recipients. Clin Transpl.
2016;30:1074–1081.
17. Diaz-Molina B, Tavira B, Lambert JL, et al. Effect of CYP3A5, CYP3A4, and
ABCB1 genotypes as determinants of tacrolimus dose and clinical out-
comes after heart transplantation. Transplant Proc. 2012;44:2635–2638.
18. Kniepeiss D, Renner W, Trummer O, et al. The role of CYP3A5 genotypes
in dose requirements of tacrolimus and everolimus after heart transplanta-
tion. Clin Transpl. 2011;25:146–150.
19. Uno T, Wada K, Matsuda S, et al. Impact of the CYP3A5*1 allele on the
pharmacokinetics of tacrolimus in Japanese heart transplant patients.
Eur J Drug Metab Pharmacokinet. 2018;43:665–673.
20. de Denus S, Zakrzewski M, Barhdadi A, et al. Association between renal
function and CYP3A5 genotype in heart transplant recipients treated with
calcineurin inhibitors. J Heart Lung Transplant. 2011;30:326–331.
21. Benza RL, Coffey CS, Pekarek DM, et al. Transforming growth factor-beta
polymorphisms and cardiac allograft rejection. J Heart Lung Transplant.
2009;28:1057–1062.
22. Densem CG, Hutchinson IV, Cooper A, et al. Polymorphism of the
transforming growth factor-beta 1 gene correlates with the development
of coronary vasculopathy following cardiac transplantation. J Heart Lung
Transplant. 2000;19:551–556.
23. Densem CG, Hutchinson IV, Yonan N, et al. Donor and recipient-
transforming growth factor-beta 1 polymorphism and cardiac transplant-
related coronary artery disease. Transpl Immunol. 2004;13:211–217.
24. Filippo S, Zeevi A, McDade KK, Bastien O, Webber SA. Impact of
TGFbeta1 gene polymorphisms on acute and chronic rejection in pediat-
ric heart transplant allografts. Transplantation. 2006;81:934–939.
25. Holweg CT, Baan CC, Balk AH, et al. The transforming growth factor-
beta1 codon 10 gene polymorphism and accelerated graft vascular disease
after clinical heart transplantation. Transplantation. 2001;71:1463–1467.
26. Aziz T, Hasleton P, Hann AW, et al. Transforming growth factor beta in re-
lation to cardiac allograft vasculopathy after heart transplantation.
J Thorac Cardiovasc Surg. 2000;119:700–708.
6 Transplantation DIRECT ■ 2019 www.transplantationdirect.com27. Di Filippo S, Zeevi A, McDade KK, et al. Impact of TGFbeta1 gene poly-
morphisms on late renal function in pediatric heart transplantation. Hum
Immunol. 2005;66:133–139.
28. van deWetering J, Weimar CH, Balk AH, et al. The impact of transforming
growth factor-beta1 gene polymorphism on end-stage renal failure after
heart transplantation. Transplantation. 2006;82:1744–1748.
29. Baan CC, Balk AH, Holweg CT, et al. Renal failure after clinical heart trans-
plantation is associated with the TGF-beta 1 codon 10 gene polymor-
phism. J Heart Lung Transplant. 2000;19:866–872.
30. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. N Engl
J Med. 1987;316:1388–1393.
31. Shen DW, Fojo A, Chin JE, et al. Human multidrug-resistant cell lines: in-
creased mdr1 expression can precede gene amplification. Science.
1986;232:643–645.
32. Zhao JJ, Wang D, Yao H, et al. CTLA-4 and MDR1 polymorphisms in-
crease the risk for ulcerative colitis: a meta-analysis. World J
Gastroenterol. 2015;21:10025–10040.
33. Safa AR, Stern RK, Choi K, et al. Molecular basis of preferential resistance
to colchicine in multidrug-resistant human cells conferred by Gly-185—
Val-185 substitution in P-glycoprotein. Proc Natl Acad Sci U S A. 1990;
87:7225–7229.
34. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nu-
cleotide polymorphisms on the pharmacokinetics and pharmacodynam-
ics of calcineurin inhibitors: part II.Clin Pharmacokinet. 2010;49:207–221.
35. Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nu-
cleotide polymorphisms on the pharmacokinetics and pharmacodynam-
ics of calcineurin inhibitors: part I. Clin Pharmacokinet. 2010;49:141–175.
36. Wolking S, Schaeffeler E, Lerche H, et al. Impact of genetic polymor-
phisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and poten-
tial clinical implications: update of the literature.Clin Pharmacokinet. 2015;
54:709–735.
37. Llaudo I, ColomH, Gimenez-Bonafe P, et al. Do drug transporter (ABCB1)
SNPs and P-glycoprotein function influence cyclosporine and macrolides
exposure in renal transplant patients? Results of the pharmacogenomic
substudy within the symphony study. Transpl Int. 2013;26:177–186.
38. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes
P450 in drug metabolism and clinical response. Trends Pharmacol Sci.
1992;13:434–439.
39. Xi B, Wang C, Liu L, et al. Association of the CYP3A5 polymorphism
(6986G>a) with blood pressure and hypertension. Hypertens Res.
2011;34:1216–1220.
40. Dai Y, Hebert MF, Isoherranen N, et al. Effect of CYP3A5 polymorphism on
tacrolimus metabolic clearance in vitro. Drug Metab Dispos. 2006;34:
836–847.
41. Jacobson PA, Oetting WS, Brearley AM, et al. Novel polymorphisms as-
sociated with tacrolimus trough concentrations: results from a multicenter
kidney transplant consortium. Transplantation. 2011;91:300–308.
42. Kobashigawa JA, Patel J, Furukawa H, et al. Five-year results of a ran-
domized, single-center study of tacrolimus vsmicroemulsion cyclosporine
in heart transplant patients. J Heart Lung Transplant. 2006;25:434–439.
43. Oetting WS, Schladt DP, Guan W, et al. Genomewide association
study of tacrolimus concentrations in African American kidney trans-
plant recipients identifies multiple CYP3A5 alleles. Am J Transplant.
2016;16:574–582.
44. Oetting WS, Wu B, Schladt DP, et al. Genome-wide association study
identifies the common variants in CYP3A4 and CYP3A5 responsible for
variation in tacrolimus trough concentration in Caucasian kidney trans-
plant recipients. Pharm J. 2018;18:501–505.
45. Attisano L, Wrana JL, Lopez-Casillas F, et al. TGF-beta receptors and ac-
tions. Biochim Biophys Acta. 1994;1222:71–80.
46. Bommireddy R, Doetschman T. TGFbeta1 and Treg cells: alliance for
tolerance. Trends Mol Med. 2007;13:492–501.
47. Morris DR, Moxon JV, Biros E, et al. Meta-analysis of the association be-
tween transforming growth factor-beta polymorphisms and complications
of coronary heart disease. PLoS One. 2012;7:e37878.
48. Hutchinson IV. The role of transforming growth factor-beta in transplant re-
jection. Transplant Proc. 1999;31:9S–13S.49. Morris-Stiff G. TGFbeta-1 and the development of chronic graft nephrop-
athy: relative roles of gene, mRNA and protein. Ann R Coll Surg Engl.
2005;87:326–330.
50. Awad MR, Webber S, Boyle G, et al. The effect of cytokine gene polymor-
phisms on pediatric heart allograft outcome. J Heart Lung Transplant.
2001;20:625–630.
51. Bijlsma FJ, van der Horst AA, Tilanus MG, et al. No association between
transforming growth factor beta gene polymorphism and acute allograft
rejection after cardiac transplantation. Transpl Immunol. 2002;10:43–47.
52. Tambur AR, Pamboukian S, CostanzoMR, et al. Genetic polymorphism in
platelet-derived growth factor and vascular endothelial growth factor are
significantly associated with cardiac allograft vasculopathy. J Heart Lung
Transplant. 2006;25:690–698.
53. Vamvakopoulos JE, Taylor CJ, Green C, et al. Interleukin 1 and chronic re-
jection: possible genetic links in human heart allografts. Am J Transplant.
2002;2:76–83.
54. DensemCG, Hutchinson IV, YonanN, et al. TGF-beta gene polymorphism
does not influence the rise in creatinine following cardiac transplantation.
Transpl Immunol. 1999;7:247–249.
55. Lacha J, Hubacek JA, Viklicky O, et al. TGF-beta1 gene polymorphism is a
risk factor for renal dysfunction in heart transplant recipients. Transplant
Proc. 2001;33:1567–1569.
56. Lachance K, Barhdadi A, Mongrain I, et al. PRKCB is associated with cal-
cineurin inhibitor-induced renal dysfunction in heart transplant recipients.
Pharmacogenet Genomics. 2012;22:336–343.
57. McDaniel O, Perrin Roten D, Yamout SZ, et al. Cytokine gene polymor-
phism might affect the outcome of clinical rejection in cardiac transplanta-
tion. J Appl Res. 2004;5:68–80.
58. Girnita DM, Ohmann EL, Brooks MM, et al. Gene polymorphisms impact
the risk of rejection with hemodynamic compromise: a multicenter study.
Transplantation. 2011;91:1326–1332.
59. Densem CG, Hutchinson IV, Yonan N, et al. Influence of interleukin-10
polymorphism on the development of coronary vasculopathy following
cardiac transplantation. Transpl Immunol. 2003;11:223–228.
60. Girnita DM, Brooks MM, Webber SA, et al. Genetic polymorphisms im-
pact the risk of acute rejection in pediatric heart transplantation: a multi-
institutional study. Transplantation. 2008;85:1632–1639.
61. Gourley IS, Denofrio D, RandW, et al. The effect of recipient cytokine gene
polymorphism on cardiac transplantation outcome. Hum Immunol. 2004;
65:248–254.
62. Bijlsma FJ, Bruggink AH, HartmanM, et al. No association between IL-10
promoter gene polymorphism and heart failure or rejection following car-
diac transplantation. Tissue Antigens. 2001;57:151–153.
63. O'Brien RP, Phelan PJ, Conroy J, et al. A genome-wide association study
of recipient genotype and medium-term kidney allograft function. Clin
Transpl. 2013;27:379–387.
64. Pihlstrom HK, Mjoen G, Mucha S, et al. Single nucleotide polymorphisms
and long-term clinical outcome in renal transplant patients: a validation
study. Am J Transplant. 2017;17:528–533.
65. McCaughan JA, McKnight AJ, Maxwell AP. Genetics of new-onset diabe-
tes after transplantation. J Am Soc Nephrol. 2014;25:1037–1049.
66. Ghisdal L, BaronC, Lebranchu Y, et al. Genome-wide association study of
acute renal graft rejection. Am J Transplant. 2017;17:201–209.
67. Sanders ML, Karnes JH, Denny JC, et al. Clinical and genetic factors as-
sociated with cutaneous squamous cell carcinoma in kidney and heart
transplant recipients. Transplant Direct. 2015;1.
68. Hernandez-Fuentes MP, Franklin C, Rebollo-Mesa I, et al. Long- and
short-term outcomes in renal allografts with deceased donors: a large re-
cipient and donor genome-wide association study. Am J Transplant.
2018;18:1370–1379.
69. International Genetics & Translational Research in Transplantation Network
(iGeneTRAiN). Design and implementation of the International Genetics
and Translational Research in Transplantation Network. Transplantation.
2015;99:2401–2412.
70. Li YR, van Setten J, Verma SS, et al. Concept and design of a genome-
wide association genotyping array tailored for transplantation-specific
studies. Genome Med. 2015;7:90.
